Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2011

01-11-2011 | Original Paper

Antidepressant Treatment and Adherence to Antiretroviral Medications Among Privately Insured Persons with HIV/AIDS

Authors: Ayse Akincigil, Ira B. Wilson, James T. Walkup, Michele J. Siegel, Cecilia Huang, Stephen Crystal

Published in: AIDS and Behavior | Issue 8/2011

Login to get access

Abstract

In order to examine relationships between depression treatments (antidepressant and/or psychotherapy utilization) and adherence to antiretroviral therapy (ART), we conducted a retrospective analysis of medical and pharmacy insurance claims for privately insured persons living with HIV/AIDS (PLWHA) diagnosed with depression (n = 1,150). Participants were enrolled in 80 insurance plans from all 50 states. Adherence was suboptimal. Depression treatment initiators were significantly more likely to be adherent to ART than the untreated. We did not observe an association between psychotherapy utilization and ART adherence, yet given the limitations of the data (e.g., there is no information on types of psychological treatment and its targets), the lack of association should not be interpreted as lack of efficacy.
Literature
1.
Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002;25:464–70.PubMedCrossRef
2.
Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29:147–55.PubMedCrossRef
3.
Koenig HG. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry. 1998;20:29–43.PubMedCrossRef
4.
Schmitz N, Wang J, Malla A, Lesage A. Joint effect of depression and chronic conditions on disability: results from a population-based study. Psychosom Med. 2007;69:332–8.PubMedCrossRef
5.
Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS. Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med. 2003;1:15–21.PubMedCrossRef
6.
7.
Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff (Millwood). 2001;20:64–78.CrossRef
8.
Butters MA, Becker JT, Nebes RD, et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. 2000;157:1949–54.PubMedCrossRef
9.
Norwood R. Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2006;12:113–7.PubMedCrossRef
10.
Schweitzer RD, Head K, Dwyer JW. Psychological factors and treatment adherence behavior in patients with chronic heart failure. J Cardiovasc Nurs. 2007;22:76–83.PubMed
11.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.PubMedCrossRef
12.
Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry. 2003;54:307–16.PubMedCrossRef
13.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.PubMedCrossRef
14.
Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–95.PubMedCrossRef
15.
Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.PubMedCrossRef
16.
Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339–47.PubMedCrossRef
17.
Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–31.PubMedCrossRef
18.
Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282–92.PubMedCrossRef
19.
Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–70.PubMedCrossRef
20.
Battaglioli-DeNero AM. Strategies for improving patient adherence to therapy and long-term patient outcomes. J Assoc Nurses AIDS Care. 2007;18:S17–22.PubMedCrossRef
21.
Nachega JB, Trotta MP, Nelson M, Ammassari A. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep. 2009;6:121–9.PubMedCrossRef
22.
Schonnesson LN, Williams ML, Ross MW, Diamond PM, Keel B. Three types of adherence to HIV antiretroviral therapy and their association with AIDS diagnosis, medication side-effects, beliefs about antiretroviral therapy, and beliefs about HIV disease. Int J STD AIDS. 2007;18:369–73.PubMedCrossRef
23.
Bouhnik AD, Preau M, Vincent E, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005;10:53–61.PubMed
24.
Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384–90.PubMedCrossRef
25.
Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr. 2010;53:266–72.PubMedCrossRef
26.
Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82–92.PubMedCrossRef
27.
Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167–73.PubMedCrossRef
28.
Simoni JM, Frick PA, Lockhart D, Liebovitz D. Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care STDS. 2002;16:431–9.PubMedCrossRef
29.
Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–9.PubMedCrossRef
30.
Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136–9.PubMed
31.
Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248–57.PubMedCrossRef
32.
Walkup J, Wei W, Sambamoorthi U, Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q. 2008;79:43–53.PubMedCrossRef
33.
Ferrando SJ, Freyberg Z. Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry. 2008;20:61–71.PubMedCrossRef
34.
Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection, AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psychiatry. 1997;19:89–97.PubMedCrossRef
35.
Ferrando SJ, Wapenyi K. Psychopharmacological treatment of patients with HIV and AIDS. Psychiatr Q. 2002;73:33–49.PubMedCrossRef
36.
37.
Imel ZE, Malterer MB, McKay KM, Wampold BE. A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia. J Affect Disord. 2008;110:197–206.PubMedCrossRef
38.
Safren S, Hendriksen E, Mayer K, et al. Cognitive-behavioral therapy for HIV medication adherence and depression. Cogn Behav Pract. 2004;11:415–24.CrossRef
39.
Safren SA, O’Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1–10.PubMedCrossRef
40.
Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Rev. ed. Atlanta: U.S. Department of Health and Human Services; 2007.
41.
Crystal S, Akincigil A, Sambamoorthi U, et al. The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr. 2003;33(Suppl 2):S76–83.PubMed
42.
Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization Study. JAMA. 1999;281:2305–15.PubMedCrossRef
43.
44.
Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Ettner SL. Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. J Acquir Immune Defic Syndr. 2008;47:449–58.PubMedCrossRef
45.
Walkup JT, Wei W, Sambamoorthi U, Crystal S. Sensitivity of an AIDS case-finding algorithm: who are we missing? Med Care. 2004;42:756–63.PubMedCrossRef
46.
Wilson IB, Tchetgen E, Spiegelman D. Patterns of adherence with antiretroviral medications: an examination of between-medication differences. JAcquir Immune Defic Syndr. 2001;28:259–63.
47.
Crepaz N, Passin WF, Herbst JH, et al. Meta-analysis of cognitive-behavioral interventions on HIV-positive persons’ mental health and immune functioning. Health Psychol. 2008;27:4–14.PubMedCrossRef
48.
Himelhoch S, Medoff DR, Oyeniyi G. Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS. 2007;21:732–9.PubMedCrossRef
49.
Arean PA, Cook BL. Psychotherapy and combined psychotherapy/pharmacotherapy for late life depression. Biol Psychiatry. 2002;52:293–303.PubMedCrossRef
50.
Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009;26:279–88.PubMedCrossRef
51.
Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry. 1998;55:452–7.PubMedCrossRef
52.
Becker SL, Dezii CM, Burtcel B, Kawabata H, Hodder S. Young HIV-infected adults are at greater risk for medication nonadherence. MedGenMed. 2002;4:21.PubMed
53.
Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19:1111–7.PubMedCrossRef
54.
Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–65.PubMedCrossRef
55.
Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432–8.PubMedCrossRef
56.
Wilson IB, Jacobson D. Regarding: “Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients”. J Acquir Immune Defic Syndr. 2006;41:254–5. author reply 255.PubMedCrossRef
57.
Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic medications among HIV-infected patients in the United States. Am J Psychiatry. 2003;160:547–54.PubMedCrossRef
58.
Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848–56.PubMedCrossRef
59.
Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44:471–7.PubMedCrossRef
60.
Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43:78–84.PubMedCrossRef
61.
Acri T, TenHave TR, Chapman JC, Bogner HR, Gross R. Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. AIDS Behav. 2008;14:748–54.PubMedCrossRef
Metadata
Title
Antidepressant Treatment and Adherence to Antiretroviral Medications Among Privately Insured Persons with HIV/AIDS
Authors
Ayse Akincigil
Ira B. Wilson
James T. Walkup
Michele J. Siegel
Cecilia Huang
Stephen Crystal
Publication date
01-11-2011
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2011
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9938-6

Other articles of this Issue 8/2011

AIDS and Behavior 8/2011 Go to the issue

Original Paper

Depression and Neurocognitive Performance in Portuguese Patients Infected with HIV

Original Paper

Psychiatric Symptom Typology in a Sample of Youth Receiving Substance Abuse Treatment Services: Associations with Self-Reported Child Maltreatment and Sexual Risk Behaviors

Original Paper

Evaluation of a Peer Network-Based Sexual Risk Reduction Intervention for Men in Beer Halls in Zimbabwe: Results from a Randomized Controlled Trial

Original Paper

An Interrupted Time Series Evaluation of a Hepatitis C Intervention for Persons with HIV

Original Paper

Results of a Randomized Controlled Trial of a Peer Mentor HIV/STI Prevention Intervention for Women Over an 18 Month Follow-Up

Original Paper

Longitudinal Change in Cognitive Function and Medication Adherence in HIV-Infected Adults

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits